Cargando...
DPP4 IN CARDIOMETABOLIC DISEASE: RECENT INSIGHTS FROM THE LABORATORY AND CLINICAL TRIALS OF DPP4 INHIBITION
The discovery of incretin-based medications represents a major therapeutic advance in the pharmacologic management of Type 2 diabetes (T2DM), as these agents avoid hypoglycemia, weight gain and simplify the management of T2DM. Dipeptidyl peptidase-4 (CD26, DPP4) inhibitors (DPP4i) are the most widel...
Gardado en:
| Publicado en: | Circ Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4394189/ https://ncbi.nlm.nih.gov/pubmed/25858071 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.116.305665 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|